Syntekabio News

This is selected news for Syntekabio, which is filed under Sectors / Healthtech. There are 23 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/4/2022 Roundup: AITRICS' AI sepsis prediction software gets cleared in South Korea and more briefs
... other patient information to come up with a prediction. AITRICS is currently working with Cleveland Clinic to validate VitalCare's performance, utilising volumes of clinical data. Syntekabio launches cloud service platform for AI drug discovery South Korean biotechnology company Syntekabio has unveiled its cloud service platform for AI-based drug discovery ...
MobiHealthNews
11/4/2022 Roundup: AITRICS’ AI sepsis prediction software gets cleared in South Korea and more briefs & More News
... patient information to come up with a prediction. AITRICS is currently working with Cleveland Clinic to validate VitalCare's performance, utilising volumes of clinical data. Syntekabio launches cloud service platform for AI drug discovery South Korean biotechnology company Syntekabio has unveiled its cloud service platform for AI-based drug discovery ...
upexampaper.com
10/13/2022 CONTEMPORARY AMPEREX TECHNOLOGY CO (300750) Syntekabio and MDBioLab Collaborate on Groundbreaking Anticancer Research
Syntekabio Syntekabio and MDBioLab Collaborate on Groundbreaking Anticancer Research 12-Oct-2022 / 19:15 CET/CEST Syntekabio and MDBioLab Collaborate on Groundbreaking Anticancer Research (226330:KOSDAQ) Syntekabio's AI platform DeepMatcher¬AE will verify and expand the application of MD102 developed by MDBioLab News release by Syntekabio, Inc. New York, NY ...
researchpool.com
10/12/2022 Syntekabio and MDBioLab Collaborate on Groundbreaking Anticancer Research (226330:KOSDAQ)
News Direct-- Syntekabio (226330:KOSDAQ)(226330:KS), an AI drug discovery and development company, announced a joint research partnership with MDBioLab, an innovative new anticancer drug development company based in South Korea. Syntekabio's AI platform DeepMatcher¬AE is used to predict compound-target protein binding to identify the mechanism ...
winslowevanscrocker.com
9/26/2022 Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen
New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS‚N¢ at the CRI-ENCI-AACR International Cancer Immunotherapy Conference ( CICON22 ): Translating Science into Survival, Sep. 28 ‚Ai Oct. 1 ...
Globe Newswire
9/26/2022 Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
Syntekabio Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22 Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22 New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will ...
Yahoo News
9/26/2022 Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
New York, N.Y., United States - 09-26-2022 ( PR Distribution‚N¢ ) - Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS‚N¢ at the CRI-ENCI-AACR International Cancer Immunotherapy Conference ( CICON22 ): Translating Science into Survival, Sep. 28 ‚Ai Oct. 1, 2022 ...
post-gazette.com
9/26/2022 Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
New York, N.Y., United States - 09-26- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS‚N¢ at the CRI-ENCI-AACR International Cancer Immunotherapy Conference ( CICON22 ): Translating Science into Survival, Sep. 28 ‚Ai Oct. 1, 2022. Hyun Joo, Ph.D ...
winslowevanscrocker.com
9/26/2022 SYNTEKABIO INC (226330) Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22 New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS‚N¢ at the CRI-ENCI-AACR International ...
researchpool.com
9/21/2022 SyntekaBio (226330.KQ)(226330:KS), an AI drug disc
SyntekaBio (226330.KQ)(226330:KS), an AI drug discovery and development company, announced the successful completion of its DeepMatcher¬AE 2.0 performance verification. The advanced version of an AI small molecule drug discovery technology is ready to launch in the global market. The company opened its regional U.S. office in ...
wapakdailynews.com
9/21/2022 SYNTEKABIO INC (226330) EQS-News: Advanced AI Drug Development Platform DeepMatcher® 2.0 Launches Worldwide (226330.KQ)
EQS-News: Syntekabio, Inc. Advanced AI Drug Development Platform 'DeepMatcher¬AE' 2.0 Launches Worldwide (226330.KQ) 21.09.2022 / 16:08 CET/CEST The issuer is solely responsible for the content of this announcement. SyntekaBio (226330.KQ)(226330:KS), an AI drug discovery and development company, announced the successful completion of its DeepMatcher ...
researchpool.com
5/15/2020 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
DAEJEON, South Korea Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company , presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020 American Association for Cancer Research (AACR) Annual Meeting, today at 00:00 ...
BioSpace
5/15/2020 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
PR Newswire DAEJEON, South Korea, May 15, 2020 STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect. Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor ...
gurufocus.com
5/15/2020 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect. Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remission (CR) of tumor and long-term survival benefit. Subsequent nonclinical development ...
PR Newswire